NeurAxis Posts Record Q2 2026 Results On PENFS Growth
NeurAxis (NRXS) reported Q2 2026 revenue of $1.9M, up 116% from $0.9M in Q2 2025, citing expanded payer coverage after Category I CPT code assignment for PENFS. Gross margin rose 230 bps. Operating cash use improved to $1.0M, with cash of $8.3M at June 30, 2026. The company also cited VA contract access and FDA clearance for IB-Stim.
How this was made
The 30-second read
Why it matters
Q2 results and the reimbursement and regulatory milestones (Category I CPT effective Jan 2026, VA FSS contract, FDA clearance for abdominal pain in functional dyspepsia ages 8+) can change near-term revenue expectations and payer adoption assumptions.
Market read
Traders can reassess NRXS based on reported Q2 financials and multiple commercialization catalysts that directly support reimbursement-driven demand.
What to watch
The article does not provide full-year guidance, backlog, or detailed cash burn trend beyond operating cash used, which are key for valuing early-commercialization medtech.
Background
NeurAxis is a neuromodulation-focused medical company; this update centers on PENFS (IB-Stim) commercialization drivers.
Ticker impact
NeurAxis reported Q2 2026 revenue of $1.9M, up 116% YoY, citing PENFS payer expansion after Category I CPT code effectiveness.
Likely positive bias for the stock versus prior expectations, though magnitude may be tempered by small absolute revenue and cash burn context.
The article provides multiple concrete commercialization milestones plus reported financials, but it lacks guidance, consensus comparisons, or detailed margin/cash-flow trajectory beyond the quarter.
Market effects
Reinforces that reimbursement and coding changes can rapidly shift adoption for neuromodulation devices, potentially supporting sentiment across small-cap medtech peers.
No specific regional demand signal beyond US payer and VA access.
Primarily US reimbursement and FDA clearance, with limited direct global read-through from this text.
Counterpoint
Despite triple-digit YoY growth, the absolute revenue base is small ($1.9M), so the move may fade if follow-through or scaling costs do not materialize.
Key entities
- companyNeurAxis, Inc.
Reported Q2 2026 results and highlighted PENFS commercialization catalysts including CPT coding, VA access, and FDA clearance.
- productPENFS (IB-Stim)
Neuromodulation therapy whose adoption is supported by reimbursement and regulatory expansions described in the article.
- regulatory/reimbursementCategory I CPT code assignment
Became effective January 2026 for PENFS procedures, cited as a driver of payer coverage expansion.
- contractVeterans Affairs Federal Supply Schedule contract
Awarded contract cited as opening access to approximately 7 million VA patients annually.
- regulatoryFDA clearance for IB-Stim
Cleared for treating abdominal pain in functional dyspepsia for patients aged 8 and older, expanding the addressable market.
